2,043 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Lifestyle Asset Management Inc.

Lifestyle Asset Management Inc. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 2,043 shares of the company’s stock, valued at approximately $262,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Redmont Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $34,000. Leeward Financial Partners LLC acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at about $222,000. Tradewinds Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 2.0% during the 1st quarter. Tradewinds Capital Management LLC now owns 5,055 shares of the company’s stock worth $649,000 after purchasing an additional 100 shares in the last quarter. Azzad Asset Management Inc. ADV grew its stake in shares of Novo Nordisk A/S by 0.6% in the 1st quarter. Azzad Asset Management Inc. ADV now owns 35,168 shares of the company’s stock valued at $4,516,000 after buying an additional 193 shares during the period. Finally, Kiley Juergens Wealth Management LLC bought a new stake in Novo Nordisk A/S in the 1st quarter valued at about $2,126,000. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price objective on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday. Argus upped their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. Finally, The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective for the company. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Stock Down 2.7 %

NVO traded down $3.87 during mid-day trading on Wednesday, reaching $139.11. 7,455,753 shares of the stock were exchanged, compared to its average volume of 4,481,115. The company has a 50 day moving average price of $135.69 and a two-hundred day moving average price of $124.37. The stock has a market capitalization of $624.26 billion, a PE ratio of 48.68, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.